Immunovant Inc (IMVT NASDAQ) stock market data APIs
$37.3985
-0.28(-0.7%)
as of September 17, 2026
Try our APIs with
free plan!
Immunovant Inc Financial Data Overview
Price chart is built with
Anychart
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Prev. Close
37.3985
Open
37.1165
High
37.8932
Low
36.1995
52 wk Range
14.58-45.42
Market Cap
7 777 M
Shares Outstanding
207 M
EPS
-0.75
Beta
0.81
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Immunovant Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Immunovant Inc data using free add-ons & libraries
Get Immunovant Inc Fundamental Data
Immunovant Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -565 606 976
- Earnings Per Share: -2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-06
- EPS/Forecast: -0.66
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Immunovant Inc News
New
Immunovant (IMVT) Stock Looks Expensive Based On Its Book Value
Immunovant has delivered very strong long term returns, and that kind of share price journey naturally raises the question of whether the current valuation still lines up with the company's book value...
Is Immunovant (IMVT) Undervalued After Its Pullback to $37.36?
Immunovant (IMVT) has drawn fresh attention after recent trading left the stock around $37.36, with short term moves weaker but a strong total return profile over the past year and beyond. Recent tra...
Rosnilimab Emerges as a Potential Advance in Rheumatoid Arthritis as Physicians Look to the Next Wave of Pipeline Innovation
New Spherix Global Insights research finds rheumatologists estimate 16% of rheumatoid arthritis patients are refractory to treatment, underscoring continued demand for differentiated therapies despite...
Immunovant's Risk/Reward Profile Balanced After Recent Rally, UBS Says
Immunovant (IMVT) has broad diversification with encouraging updates but faces balanced risk/reward PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscrip...
Get Immunovant Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
